SCHEMBL4827007

SCHEMBL4827007

NC1=c2ccoc2=NCN1c1ccc(NS(=O)(=O)c2ccc(-c3ccc(Cl)c(Cl)c3)cc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ PTGS2 P35354 2/20 0.41
▸ PTGES2 Q9H7Z7 1/20 0.39
▸ PFKFB3 Q16875 1/20 0.39
▸ HSPD1 P10809 1/20 0.38
▸ PTPN2 P17706 1/20 0.38
▸ PTPN1 P18031 1/20 0.38
▸ PTPN5 P54829 1/20 0.38
▸ HSPE1 P61604 1/20 0.38
▸ NPY5R Q15761 3/20 0.37
▸ DRD2 P14416 1/20 0.37
▸ HTR2A P28223 1/20 0.37
▸ HTR2C P28335 1/20 0.37
▸ DRD3 P35462 1/20 0.37
▸ HTR6 P50406 1/20 0.37
▸ KIT P10721 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ CYP3A4 P08684 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4829022 0.92 MAPT (0.49) MAPTALDH1A1LMNAPTGS2HSPD1
SCHEMBL4831414 0.88 PGR (0.46) MAPTALDH1A1LMNAPTGES2NPSR1
SCHEMBL4830862 0.85 PGR (0.44) MAPTLMNAHSPD1PTPN2PTPN1
SCHEMBL4833803 0.85 POLB (0.47) MAPTALDH1A1LMNADRD2DRD3
SCHEMBL4834472 0.84 CYP3A4 (0.47) HTR6CYP3A4CYP2D6PSEN1PSEN2
SCHEMBL4836618 0.84 MEN1 (0.42) MAPTALDH1A1LMNADRD2HTR2A
SCHEMBL4834402 0.83 ALDH1A1 (0.49) MAPTALDH1A1LMNANPY5RCYP3A4
SCHEMBL4833946 0.83 KEAP1 (0.46) MAPTALDH1A1LMNANPY5RHTR6
SCHEMBL4834398 0.82 MAPT (0.47) MAPTALDH1A1LMNAHSPD1PTPN2
SCHEMBL4827030 0.82 ALDH1A1 (0.47) MAPTALDH1A1LMNAMEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 — — US claimed
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US claimed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP claimed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO claimed
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 — — US disclosed
US-7427623-B2 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof SMITHKLINE BEECHAM CORPORATION (US) 2008-09-23 — — US disclosed
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US disclosed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP disclosed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004142-A1 Chemical compounds TIE1, KDR, TEK MAPT 2499/4885ALDH1A1 906/4885LMNA 4230/4885
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF TIE1, TEK, KDR MAPT 2424/4885ALDH1A1 1144/4885LMNA 4131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback